Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 22, 2006

Valeant Pharmaceuticals Sells Discovery and Preclinical Assets to Ardea Biosciences

  • Valeant Pharmaceuticals sold some of its discovery and preclinical assets to Ardea Biosciences, formerly known as Intrabiotics Pharmaceuticals. The sale includes the rights to Valeant’s HIV and cancer development programs.

    Under the terms of the agreement, Ardea will make payments to Valeant upon the achievement of clinical milestones for both HIV and cancer programs. Valeant will retain an option, exercisable upon the completion of Phase IIb studies by Ardea, to reacquire rights to commercialize its HIV program outside of the U.S. and Canada upon Ardea’s completion of Phase III trials.

    Ardea will pay Valeant development milestones and royalties upon its commercialization of the HIV and cancer programs. Valeant would make milestone and royalty payments to Ardea related to the clinical advancement and commercialization of the HIV program should Valeant exercise its option to this program.

    According to Timothy C. Tyson, Valeant’s president and CEO, “The sale to Ardea is another significant step forward in the execution of our restructuring initiative. The agreement will further the development of important programs for HIV and other therapies while allowing us to retain an interest in the commercial rights to our HIV compounds.”

     



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »